Veru reports fiscal 2025 results, plans obesity drug trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
December 17, 2025 6:30 AM EST-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA --
-- Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body composition improvements --
-- Company plans to initiate Phase 2 PLATEAU clinical study in calendar Q1 2026 --
-- Post fiscal year end, company completed public offering for net proceeds of approximately $23.4 million... More
